Evidence map›Paper›PMID 40329104›Full record

ArticleCell death and differentiation2025

Depletion of oxysterol-binding proteins by OSW-1 triggers RIP1/RIP3-independent necroptosis and sensitization to cancer immunotherapy.

Xinyan Lu, Dongshi Chen, Min Wang, Xiangping Song, Kaylee Ermine, Suisui Hao, Anupma Jha, Yixian Huang, Ying Kang, Haibo Qiu and 5 more

Abstract read
In one paragraph

Article in Cell death and differentiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Regulated cell death programs shaping cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  4. Organelle contact sites in cancer cells.Cell death & disease · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xinyan LuDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.
Dongshi ChenDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.ORCID 0000-0002-8973-5606
Min WangDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Xiangping SongDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kaylee ErmineDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Suisui HaoDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.
Anupma JhaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yixian HuangUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ying KangDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
Haibo QiuDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.ORCID 0009-0000-3283-8359
Heinz-Josef LenzDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.ORCID 0000-0003-2178-9568
Song LiUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-1658-949X
Zhendong JinDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-1672-513X
Jian YuDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.ORCID 0000-0002-4021-1000
Lin ZhangDepartment of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA. lzhang24@usc.edu.ORCID 0000-0003-0018-3903

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VERONICA WENDY SETIAWAN · 1985 to 2026
$181.4M
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dan Paul Zandberg · 1988 to 2026
$158.0M
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancerR01CA217141 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NIKOLOVSKA-COLESKA, ZANETA, ZHANG, LIN · 2017 to 2021
$2.6M
STING-dependent Intestinal Regeneration upon Radiation InjuryR01CA260900 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YU, JIAN · 2022 to 2025
$2.5M
Translation addiction and targeting in colon cancerR01CA215481 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YU, JIAN · 2018 to 2022
$2.3M
Targeting defective necroptosis in colorectal cancerR01CA247231 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2020 to 2024
$2.3M
Role of necroptosis in colorectal cancer therapyR01CA236271 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2019 to 2023
$2.2M
BET degraders for improving colorectal cancer therapyR01CA248112 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2021 to 2025
$2.1M
Predoctoral Training in Pharmacological Sciences (Resubmission)T32GM133332 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tija C. Jacob, Francisco Jose Schopfer · 2020 to 2026
$1.8M
Role of Mcl-1 degradation in colorecal cancer therapyR01CA203028 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIN · 2016 to 2020
$1.7M
NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA203028NCI NIH HHS R01 CA215481NCI NIH HHS R01 CA217141NCI NIH HHS R01 CA236271NCI NIH HHS R01 CA247231NCI NIH HHS R01 CA248112NCI NIH HHS R01 CA260900NIGMS NIH HHS T32 GM133332U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA203028U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA215481U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA217141U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA236271U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA247231U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA248112U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA260900U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM133332
6 · The paper itself

Abstract

Oxysterol-binding proteins (OSBPs), lipid transfer proteins functioning at intracellular membrane contact sites, are recently found to be dysregulated in cancer and promote cancer cell survival. However, their role as potential targets in cancer therapy remains largely unexplored. In this study, we found OSW-1, a natural compound and OSBP inhibitor, potently and selectively kills colon cancer cells by activating a previously unknown necroptosis pathway that is independent of receptor-interacting protein 1 (RIP1) and RIP3. OSW-1 stabilizes p53 and degrades OSBPs to promote endoplasmic reticulum (ER) stress and glycogen synthase kinase 3β (GSK3β)/Tip60-mediated p53 acetylation at Lysine 120, which selectively induces its target PUMA. PUMA-mediated mitochondrial calcium influx activates calcium/calmodulin-dependent protein kinase IIδ (CamKIIδ) to promote mixed lineage kinase domain-like (MLKL) phosphorylation and necroptotic cell death. Furthermore, OSW-1-induced necroptosis is highly immunogenic and sensitizes syngeneic colorectal tumors to anti-PD-1 immunotherapy. Together, our results identified a novel RIP1/RIP3-independent necroptosis pathway underlying the extremely potent anticancer activity of OSW-1, which can be harnessed to develop new anticancer therapies by selectively stimulating antitumor immunity.

Indexed as

NecroptosisNuclear Pore Complex ProteinsReceptor-Interacting Protein Serine-Threonine KinasesReceptors, SteroidAnimalsApoptosis Regulatory ProteinsCell Line, TumorColonic NeoplasmsEndoplasmic Reticulum StressHumansMiceMice, Inbred C57BLOxysterol Binding ProteinsRNA-Binding ProteinsTumor Suppressor Protein p53AGFG1 protein, humanApoptosis Regulatory ProteinsNuclear Pore Complex ProteinsOxysterol Binding ProteinsReceptor-Interacting Protein Serine-Threonine KinasesReceptors, SteroidRIPK3 protein, humanRNA-Binding ProteinsTumor Suppressor Protein p53

Identifiers

PMID40329104
PMCPMC12572256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.